Consolidated Statements of Cash Flows (Unaudited) - USD ($)		9 Months Ended
		Sep. 30, 2015		Sep. 30, 2014
Operating activities
Net income (loss)		$ 739,134,000		$ 305,825,000
Adjustments to reconcile net income to net cash provided from (used in) operating activities:
Depreciation and amortization		603,431,000		648,737,000
Other amortization expenses		3,867,000		5,626,000
Asset Impairment Charges		2,220,000		0
Stock-based compensation expense		25,655,000		26,108,000
Loss (gain) on derivatives, net		(58,427,000)	[1]	400,000
Loss (gain) on extinguishment of debt, net		34,872,000		3,075,000
Income from unconsolidated entities		18,231,000		19,705,000
Rental income in excess of cash received		(86,739,000)		(51,017,000)
Amortization related to above (below) market leases, net		2,863,000		503,000
Net loss (gain) on sales of properties		(249,002,000)		(42,683,000)
Distributions by unconsolidated entities		435,000		8,883,000
Increase (decrease) in accrued expenses and other liabilities		42,759,000		(19,259,000)
Decrease (increase) in receivables and other assets		(42,975,000)		(51,734,000)
Net cash provided from (used in) operating activities		1,036,324,000		854,169,000
Investing activities
Cash disbursed for acquisitions		(2,489,345,000)		(991,315,000)
Cash disbursed for capital improvements to existing properties		(122,640,000)		(86,324,000)
Cash disbursed for construction in progress		(165,311,000)		(140,829,000)
Capitalized interest		(6,311,000)		(5,084,000)
Investment in real estate loans receivable		(445,985,000)		(79,264,000)
Other investments, net of payments		(129,311,000)		(39,202,000)
Principal collected on real estate loans receivable		71,111,000		46,268,000
Contributions to unconsolidated entities		(139,295,000)		(246,794,000)
Distributions by unconsolidated entities		139,557,000		38,261,000
Proceeds from (payments on) derivatives investing		103,615,000		0
Decrease (increase) in restricted cash		10,512,000		(45,346,000)
Proceeds from sales of real property		667,761,000		442,733,000
Net cash provided from (used in) investing activities		(2,505,642,000)		(1,106,896,000)
Financing activities
Net increase (decrease) under unsecured lines of credit arrangements		490,000,000		(130,000,000)
Proceeds from issuance of senior unsecured notes		743,407,000		0
Payments to extinguish senior unsecured notes		(534,546,000)		(47,591,000)
Secured debt issued		222,612,000		98,100,000
Payments on secured debt		(469,455,000)		(286,162,000)
Net proceeds from the issuance of common stock		1,641,981,000		2,260,908,000
Decrease (increase) in deferred loan expenses		(7,834,000)		(17,429,000)
Contributions by noncontrolling interests	[2]	163,105,000		5,572,000
Distributions to noncontrolling interests	[2]	(27,439,000)		(30,909,000)
Acquisitions of noncontrolling interests		(3,154,000)		(1,175,000)
Cash distributions to stockholders		(901,618,000)		(757,980,000)
Other financing activities		(27,114,000)		(844,000)
Net cash provided from (used in) financing activities		1,289,945,000		1,092,490,000
Effect of foreign currency translation on cash and cash equivalents		(2,311,000)		135,000
Increase (decrease) in cash and cash equivalents		(181,684,000)		839,898,000
Cash and cash equivalents at beginning of period		473,726,000		158,780,000
Cash and cash equivalents at end of period		292,042,000		998,678,000
Supplemental cash flow information:
Interest paid		334,511,000		365,738,000
Income taxes paid		$ 11,489,000		$ 16,672,000

[1] (1) In April 2011, we completed the acquisition of substantially all of the real estate assets of privately-owned Genesis Healthcare Corporation. In conjunction with this transaction, we received the option to acquire an ownership interest in Genesis Healthcare. In February 2015, Genesis Healthcare closed on a transaction to merge with Skilled Healthcare Group to become a publicly traded company which required us to record the value of the derivative asset due to the net settlement feature.

[2] (1) Includes amounts attributable to redeemable noncontrolling interests.